Projects

1. Romania’s National Recovery and Resilience Plan, project PNRR-III-C9-2022-I8, CF 93/15.11.2022, financing contract no. 760063/23.05.2023 New nanotherapeutic strategies for cardiac fibrosis targeting the mechanisms underlying the fibroblast to myofibroblast transition, https://heartcure.eu/

2 .Romania’s National Recovery and Resilience Plan, project PNRR-III-C9-2022-I8, CF 186/24.11.2022, contract No.: 760062/23.05.2023. Targeting Cardiac Fibrosis in Heart Failure; Challenges and Potential Solutions Based on ncRNA Therapeutics, https://www.burlaculab.com/fibrothera-about-project

Completed projects: Results

 Anti-Inflammatory N2 Neutrophils Reprogram Macrophages toward a Pro-Healing Phenotype with Increased Efferocytosis Capacity.

Mihaila et al.; Cells. Jan 23;13(3):208., 2024

 The Elevated Inflammatory Status of Neutrophils Is Related to In-Hospital Complications in Patients with Acute Coronary Syndrome and Has Important Prognosis Value for Diabetic Patients.

Barbu et al; Int J Mol Sci. 2024;25(10):5107, 2024

 Transcriptional profiling and functional analysis of N1-proinflammatory and N2 – anti-inflammatory neutrophils; immunomodulatory effect of S100A9-blockade on the pro-inflammatory N1.

Mihaila et al.; Front. Immunol., 12:708770., 2021

 The diabetic conditions or the interplay between monocytes and valvular endothelial cells aggravates endothelial dysfunction by increased permeability and enhancement monocyte transmigration.

Tucureanu et al.; Int J Mol Sci.; 25(5):3048, 2024

 Development of a 3D valve model based on native tissue and description of the effect of high glucose valvular endothelial cells phenotype;

Cecoltan et al.; Front. Cardiovasc. Med., Aug 12;8:714573, 2021

 Development of a 3D valve model based on gelatin and description of the molecular mechanisms involved in high glucose‐induced valve calcification;

Vadana et al.; J Cell Mol Med. Jun;24(11):6350-6361, 2020

Completed projects - Grants:

1. 2022-2024: PN-III-P1-1.1-PD-2021-0498 – “Impact of high glucose in valvular endothelial cells-monocyte crosstalk: molecular signatures and role in early valvular dysfunction” - VALDYSIGN

2. 2020-2023: ERA-NET NEURON Call for Joint Transnational Research Projects – “Stroke risk prediction in atherosclerosis measuring circulating complement system proteins” - STATEMENT

3. 2020-2022: PN-III-P2-2.1-PED-2019-4906 - “Development and validation of a native cardiac hydrogel for myocardial repair post-infarction” – NAMIGEL

4. 2018-2022: PN-III-P4-ID-PCCF-2016-0172 - “Targeting innate immune mechanisms to improve risk stratification and to identify future therapeutic options in myocardial infarction” – INNATE-MI

5. 2018-2021: PCCDI Complex Project nr. 13 PCCDI/2018 "Intelligent therapies for non-communicable diseases based on controlled release of pharmacological compounds from encapsulated engineered cells and targeted bio nanoparticles" - INTERA

6. 2016-2020: Competitiveness Operational Programme, Priority Axis 1/Action 1.1.4 “Targeted therapies for diabetes-related aortic valve disease” – THERAVALDIS

7. 2015-2017: PN-II-RU-TE-2014-4-0965 - Vascular cell cross-talk, induces specific microRNAs that can be relevant for atherosclerotic plaque rupture, in type 2 diabetes patients – MIRDIATRIX

8. 2011-2016:PN-II-ID-PCE-2011-3 - Molecules and mechanisms involved in cytokine and chemokine-dependent vascular inflammation as targets for novel nano-therapeutic strategies, Exploratory Research Projects – REFINATER

9. 2011-2014: European Innovative RTD Projects Proposals in Nanomedicine EuroNanoMed JTC 2010, FP7,“Nanoparticles designed to target chemokine-related inflammatory processes in vascular diseases and cancer metastasis and implementation of a biosensor to diagnose these disorders” NANODIATER